No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹8,290Prev. Close
₹8,210.5Turnover(Lac.)
₹282.55Day's High
₹8,290Day's Low
₹8,16652 Week's High
₹9,849.552 Week's Low
₹7,551.5Book Value
₹349.12Face Value
₹2Mkt Cap (₹ Cr.)
20,433.75P/E
106.82EPS
76.52Divi. Yield
0.4428 Jul 2025
12:00 AM
AGM
Announcement Date: 28 Jul, 2025
20 May 2026
12:00 AM
Board Meeting
Agenda : Audited Result
26 May 2026
12:00 AM
Dividend
Dividend Amount: 36
Record Date: 31 Jul, 2026
AstraZeneca will continue to hold the intellectual property, manage the import licence, and retain the Marketing Authorisation for the drug.
Here are some of the stocks that may see significant price movement today: ITD Cementation, Premier Energies, AstraZeneca, etc.
The approval is for two dosing forms: 120 mg/2.4 ml and 500 mg/10 ml.
The company may import the powder form of sodium zirconium cyclosilicate for preparation of oral suspension as Lokelma in 5 g and 10 g formulation.
As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land deal.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 867.79 | 765.35 | 706.92 | 583.69 |
Net Worth | 872.79 | 770.35 | 711.92 | 588.69 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 805.6 | 813.56 | 831.81 | 571 |
yoy growth (%) | -0.97 | -2.19 | 45.67 | 5.01 |
Raw materials | -311.96 | -294.95 | -305.23 | -181.09 |
As % of sales | 38.72 | 36.25 | 36.69 | 31.71 |
Employee costs | -230.21 | -219.54 | -216.7 | -153.53 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 83.04 | 127.09 | 113.97 | 43.8 |
Depreciation | -16.95 | -20.13 | -18.58 | -14.74 |
Tax paid | -21.44 | -33.79 | -41.76 | -17.89 |
Working capital | 57.86 | 101.15 | 103.65 | 52.76 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.97 | -2.19 | 45.67 | 5.01 |
Op profit growth | -36.38 | 12.23 | 160.74 | 25.31 |
EBIT growth | -34.47 | 11.35 | 162.8 | 23.38 |
Net profit growth | -33.97 | 29.2 | 178.69 | 29.22 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,940 | 147.7 | 4,70,269.65 | 1,115.14 | 0.82 | 5,641.31 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 8,388 | 74.18 | 2,22,223.75 | 891 | 0.36 | 2,974 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 5,000 | 93.29 | 1,91,325.03 | 492 | 0.67 | 4,073 | 222.76 |
Cipla Ltd CIPLA | 1,458.8 | 35.72 | 1,17,137.57 | 862.16 | 0.9 | 4,672.12 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,121.1 | 30.23 | 1,11,570.8 | 1,722 | 0.09 | 3,564.6 | 237.3 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Shilpa Divekar Nirula
Managing Director / Business Unit Head
Praveen Rao Akkinepally
Executive Director / Whole Time Director / CFO
Bhavana Agrawal
Independent Non Exe. Director
Revathy Ashok
Independent Non Exe. Director
MONICA WIDHANI
Non Executive Director
Hooi Bien Chuah
Company Sec. & Compli. Officer
Tanya Sanish
Blk N1 12th Flr Manyata Embass,
Rachenahalli Outer Ring Road,
Karnataka - 560045
Tel: 91-080-67748000
Website: http://www.astrazeneca.in
Email: comp.secy@astrazeneca.com
No. 30 Ramana Resid.,
4th Cross Sampige Rd, Malleswaram,
Bangalore - 560003
Tel: 91-80-23460815-818
Website: www.integratedindia.in
Email: alfint@vsnl.com
Summary
Astrazeneca Pharma India Limited (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates...
Read More
Reports by Astrazeneca Pharma India Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
